121 related articles for article (PubMed ID: 2113148)
21. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
Tanji S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
[TBL] [Abstract][Full Text] [Related]
22. Effects of interleukin-2, OK-432 and interferon-gamma on in vitro induction of nonspecific killer cells by concanavalin A in mice.
Mizushima Y; Iwata M; Sato M; Yano S
Tohoku J Exp Med; 1986 Jan; 148(1):79-85. PubMed ID: 3085284
[TBL] [Abstract][Full Text] [Related]
23. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
24. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432.
Wakasugi H; Kasahara T; Minato N; Hamuro J; Miyata M; Morioka Y
J Natl Cancer Inst; 1982 Oct; 69(4):807-12. PubMed ID: 6181282
[TBL] [Abstract][Full Text] [Related]
25. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
26. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
27. Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent.
Okamoto M; Ohe G; Oshikawa T; Nishikawa H; Furuichi S; Yoshida H; Matsuno T; Saito M; Sato M
Immunopharmacology; 2000 Sep; 49(3):363-76. PubMed ID: 10996034
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
Homma S; Sagawa Y; Komita H; Koido S; Nagasaki E; Ryoma Y; Okamoto M
Cancer Immunol Immunother; 2007 Aug; 56(8):1265-74. PubMed ID: 17219148
[TBL] [Abstract][Full Text] [Related]
29. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
30. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells.
Galligioni E; Quaia M; Spada A; Favaro D; Santarosa M; Talamini R; Monfardini S
Int J Cancer; 1993 Sep; 55(3):380-5. PubMed ID: 8375921
[TBL] [Abstract][Full Text] [Related]
31. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
32. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.
Wakasugi H; Oshimi K; Miyata M; Morioka Y
J Clin Immunol; 1981 Jul; 1(3):154-62. PubMed ID: 6174541
[TBL] [Abstract][Full Text] [Related]
34. Purification and characterization of interferon-gamma-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-gamma-inducing activity of OK-432.
Okamoto M; Kaji R; Kasetani H; Yoshida H; Moriya Y; Saito M; Sato M
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):232-42. PubMed ID: 8334107
[TBL] [Abstract][Full Text] [Related]
35. [Studies on the production of endogenous cytokines in patients with renal cell carcinoma].
Nakashima J; Tachibana M; Baba S; Deguchi N; Jitsukawa S; Hata M; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1992 Jul; 83(7):1110-7. PubMed ID: 1507728
[TBL] [Abstract][Full Text] [Related]
36. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
37. A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer.
Kawano Y; Watanabe M; Kubota T; Nishibori H; Kurihara N; Teramoto T; Kitajima M
Anticancer Res; 1997; 17(4A):2449-53. PubMed ID: 9252661
[TBL] [Abstract][Full Text] [Related]
38. Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation.
Katano M; Yamamoto H; Mizoguchi T; Hisatsugu T
Cancer Immunol Immunother; 1988; 27(3):198-204. PubMed ID: 3141056
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects.
Rinehart JJ; Young D; Laforge J; Colburn D; Neidhart J
J Biol Response Mod; 1987 Jun; 6(3):302-12. PubMed ID: 3110379
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
